361 related articles for article (PubMed ID: 22563432)
61. Juniper Berries Regulate Diabetes and Obesity Markers Through Modulating PPAR
Chae HS; Dale O; Mir TM; Ashfaq MK; Avula B; Walker LA; Khan IA; Khan SI
J Med Food; 2023 May; 26(5):307-318. PubMed ID: 37186895
[TBL] [Abstract][Full Text] [Related]
62. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
[TBL] [Abstract][Full Text] [Related]
63. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
64. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt.
Jia Y; Wu C; Kim J; Kim B; Lee SJ
J Nutr Biochem; 2016 Feb; 28():9-18. PubMed ID: 26878778
[TBL] [Abstract][Full Text] [Related]
65. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
66. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
67. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.
Chang CS; Tsai PJ; Sung JM; Chen JY; Ho LC; Pandya K; Maeda N; Tsai YS
Am J Pathol; 2014 Feb; 184(2):442-53. PubMed ID: 24287404
[TBL] [Abstract][Full Text] [Related]
68. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.
Gilde AJ; van der Lee KA; Willemsen PH; Chinetti G; van der Leij FR; van der Vusse GJ; Staels B; van Bilsen M
Circ Res; 2003 Mar; 92(5):518-24. PubMed ID: 12600885
[TBL] [Abstract][Full Text] [Related]
69. Peroxisome proliferator-activated receptors increase human sebum production.
Trivedi NR; Cong Z; Nelson AM; Albert AJ; Rosamilia LL; Sivarajah S; Gilliland KL; Liu W; Mauger DT; Gabbay RA; Thiboutot DM
J Invest Dermatol; 2006 Sep; 126(9):2002-9. PubMed ID: 16675962
[TBL] [Abstract][Full Text] [Related]
70. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.
Dressel U; Allen TL; Pippal JB; Rohde PR; Lau P; Muscat GE
Mol Endocrinol; 2003 Dec; 17(12):2477-93. PubMed ID: 14525954
[TBL] [Abstract][Full Text] [Related]
71. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
Grygiel-Górniak B
Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
[TBL] [Abstract][Full Text] [Related]
72. Roles of peroxisome proliferator-activated receptor-alpha and -gamma in the development of non-small cell lung cancer.
Li MY; Yuan H; Ma LT; Kong AW; Hsin MK; Yip JH; Underwood MJ; Chen GG
Am J Respir Cell Mol Biol; 2010 Dec; 43(6):674-83. PubMed ID: 20081051
[TBL] [Abstract][Full Text] [Related]
73. Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1.
Ungaro P; Mirra P; Oriente F; Nigro C; Ciccarelli M; Vastolo V; Longo M; Perruolo G; Spinelli R; Formisano P; Miele C; Beguinot F
J Biol Chem; 2012 Dec; 287(51):42951-61. PubMed ID: 23105093
[TBL] [Abstract][Full Text] [Related]
74. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
Chopra B; Georgopoulos NT; Nicholl A; Hinley J; Oleksiewicz MB; Southgate J
Cell Prolif; 2009 Oct; 42(5):688-700. PubMed ID: 19614673
[TBL] [Abstract][Full Text] [Related]
75. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Oliveira AC; Bertollo CM; Rocha LT; Nascimento EB; Costa KA; Coelho MM
Eur J Pharmacol; 2007 Apr; 561(1-3):194-201. PubMed ID: 17343847
[TBL] [Abstract][Full Text] [Related]
76. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
[TBL] [Abstract][Full Text] [Related]
77. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.
Matsui J; Terauchi Y; Kubota N; Takamoto I; Eto K; Yamashita T; Komeda K; Yamauchi T; Kamon J; Kita S; Noda M; Kadowaki T
Diabetes; 2004 Nov; 53(11):2844-54. PubMed ID: 15504964
[TBL] [Abstract][Full Text] [Related]
78. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
[TBL] [Abstract][Full Text] [Related]
79. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
80. New PPARγ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr(-/-) mice.
Silva JC; César FA; de Oliveira EM; Turato WM; Tripodi GL; Castilho G; Machado-Lima A; de Las Heras B; Boscá L; Rabello MM; Hernandes MZ; Pitta MG; Pitta IR; Passarelli M; Rudnicki M; Abdalla DS
Pharmacol Res; 2016 Feb; 104():49-60. PubMed ID: 26706782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
